Healthcare Industry News: S.A.
News Release - December 23, 2022
Hyphens Pharma Licenses Winlevi(R) for All 10 ASEAN countries from Cosmo Pharmaceuticals
Winlevi® iS.A.first-in-class topical drug for the treatment of acne approved by U.S. FDA in August 2020It will reinforce our Proprietary Brand segment's dermatological franchise
SINGAPORE, Dec. 23, 2022 -- (Healthcare Sales & Marketing Network) -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte. Ltd., has entered into exclusive license and supply agreements with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ("Cosmo") for the exclusive rights to develop and commercialize Winlevi® (clascoterone) cream 1% and all future product extension and/or improvement in the treatment of acne in 10 countrieS.A.ross Southeast AS.A.
Winlevi® (www.winlevi.com) iS.A.U.S. Food & Drug Administration ("FDA") approved novel drug with a unique mechanism of action for the topical treatment of acne in patientS.A.ed 12 yearS.A.d older. It is the first-in-class topical androgen receptor inhibitor that tackles the androgen hormone component of acne and is the first new type of acne medication approved by the FDA since 1982. As the only topical cream to treat hormonal acne directly in the skin, it offerS.A.non-antibiotic approach for acne-sufferers everywhere. Winlevi® inhibits sebum production and inflammation by targeting the androgen receptors in the sebaceous gland cells. Oral treatmentS.A.e typically prescribed to address hormonal acne, but uS.A.ly only prescribed to females. With Winlevi®, males suffering from acne, as well as females who don't want to take oral medications, can now benefit from this first-in-class treatment, making Winlevi® a game-changer in the fight against acne.
Launched in the U.S. in November 2021, Winlevi® iS.A.ready the most prescribed branded topical acne drug in the U.S. based on IQVIA data. Over 12,000 U.S. physicians have prescribed Winlevi® to date. According to the prescriptions generated, Winlevi® has been one of the most successful U.S. launches in the topical acne S.A.e in the last 15 years.
In a study involving 3,888 Singapore Chinese subjects, the estimated prevalence of acne vulgaris is 53.8%[1]. Acne can have profound social and psychological effects on adolescents or young adults when it affects their self-esteem[2]. As the first novel acne drug in decades, Winlevi® has huge potential to revolutionize the acne treatment S.A.e. Winlevi® will be Hyphens Pharma's first innovative therapeutics, deepening its dermatology pipeline.
Today, Hyphens Pharma haS.A.proprietary range of dermatological products for acne, atopic dermatitis, hyperpigmentation, and hair loss. These are available through doctors including dermatologists, paediatricians, and general practitionerS.A. well as major retail pharmacies.
Diana Harbort, President of Cosmo's Dermatology Division, said: "We are very pleased to partner with Hyphens Pharma. Their strong expertise in Southeast AS.A.gives us great confidence in their ability to gain regulatory approval and commercialise Winlevi® in the region. The success of Winlevi® in the U.S. has given us the opportunity to select the best partners in each region and to eventually make the product available to more patientS.A.ound the globe."
Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, said: "Acne iS.A.medical condition that affects millions in the AS.A. region. Yet, the medical management of acne remained largely similar due to the absence of new drugs. Winlevi® is the first new class of topical drug for the treatment of acne that iS.A.proved by U.S. FDA in nearly 40 years. We are thus very proud to be able to bring Winlevi® to doctorS.A.d patients in the entire AS.A. region. We would like to thank Cosmo for this partnership and their confidence in Hyphens Pharma. This deal also affirms Hyphens Pharma's strength aS.A.EAN's leading specialty pharmaceutical company with a strong focus on skin health. We will continue to innovate, as well as to bring to market relevant innovations from the world to our region, so as to continue serving our doctorS.A.d patients."
About Hyphens Pharma International Limited (http://www.hyphensgroup.com)
Hyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore's leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in AS.A. countries. The Group haS.A.direct presence in Singapore, Vietnam, MalayS.A. IndoneS.A.and the Philippines, and is supplemented by a marketing and distribution network covering 10 other markets – Bangladesh, Brunei, Cambodia, China, Hong Kong S.A.R., Macau S.A.R., Myanmar, Oman, South Korea and Sri Lanka.
Singapore is the Group's regional headquarters, where its strategic planning, finance, regulatory affairs, reS.A.ch and development, legal, business development and logistics operationS.A.e based. The Group's core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected AS.A. countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United S.A.es, the Group also develops, marketS.A.d sells its own proprietary range of dermatological productS.A.d health supplement products. In addition, the Group operateS.A.medical hypermart for healthcare professionals, healthcare institutionS.A.d retail pharmacies, to supply pharmaceutical productS.A.d medical supplieS.A.d an online pharmacy for doctors to prescribe and have medications delivered to their patients' homes.
About Cosmo N.V. (https://www.cosmopharma.com)
Cosmo iS.A.pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesionS.A.d to treat selected dermatological conditions. Cosmo developS.A.d manufactures products which are distributed globally by selected partners including Lialda®/Mezavant®/Mesavancol®, Uceris®/Cortiment®, Aemcolo®/ Relafalk® and Winlevi®. Cosmo haS.A.so developed medical devices for endoscopy and haS.A.partnership with Medtronic for the global distribution of GI Genius™ which useS.A.tificial intelligence to help detect potential signs of colon cancer. The company also haS.A.rich development pipeline.
This media release has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the S.A.ements or opinions made or reports contained in this media release.
The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.
[1] Heng AHS et al. Epidemiological Risk FactorS.A.sociated with Acne Vulgaris Presentation, Severity, and S.A.ring in a Singapore Chinese Population: A Cross-Sectional Study. Dermatology. 2022;238(2):226-235.
[2] Moosa AS et al. Primary care approach to managing acne. Singapore Med J. 2021 Nov;62(11):568-573.
Source: Hyphens Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!